Korro Bio (NASDAQ: KRRO) advances RNA drug toward first human tests
Rhea-AI Filing Summary
Korro Bio, Inc. (KRRO) reports that on August 19, 2026 it submitted materials to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121. KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide being developed for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders.
The planned Phase 1/2 study is designed to evaluate safety and tolerability of escalating doses, characterize pharmacokinetics, and assess effects in both healthy volunteers and participants with Urea Cycle Disorders. Additional trial details are available at ClinicalTrials.gov under identifier NCT 07773246.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Announcement date: August 19, 2026
Clinical trial phase: Phase 1/2
ClinicalTrials.gov identifier: NCT 07773246
+1 more
4 metrics
Announcement date
August 19, 2026
Date Korro Bio reported submitting to the Australian Alfred Health Human Ethics Committee
Clinical trial phase
Phase 1/2
First-in-human clinical trial stage planned for KRRO-121
ClinicalTrials.gov identifier
NCT 07773246
Registry identifier cited for the KRRO-121 Phase 1/2 clinical trial
Telephone number
(617) 468-1999
Registrant’s telephone number for Korro Bio, Inc.
Key Terms
first-in-human, GalNAc-conjugated RNA editing oligonucleotide, hyperammonemia, Urea Cycle Disorders, +2 more
6 terms
first-in-human medical
"to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121"
A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.
GalNAc-conjugated RNA editing oligonucleotide medical
"KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide in development"
hyperammonemia medical
"in development for the potential treatment of hyperammonemia in patients"
A medical condition where the level of ammonia in the blood rises above normal, becoming toxic to the brain and other organs; symptoms can range from confusion and lethargy to coma. Investors care because therapies, diagnostics, or devices that prevent or treat this condition can affect clinical trial outcomes, regulatory approval, patient safety and market opportunity—think of it as a clogged filter in the body where fixing the filter has clear value and risk implications.
Urea Cycle Disorders medical
"hyperammonemia in patients with Urea Cycle Disorders, or UCDs"
Urea cycle disorders are rare inherited conditions in which the body cannot properly convert toxic ammonia into a harmless waste product, so ammonia builds up in the blood. Think of the urea cycle as an assembly line that clears nitrogen waste; when one machine is broken, waste accumulates and can cause serious illness. Investors care because these disorders create demand for specialized treatments and diagnostics, often involve small patient populations, high development costs, and regulatory incentives that affect drug valuation and risk.
pharmacokinetics medical
"determine the safety and tolerability of escalating doses, evaluate its pharmacokinetics"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
Human Ethics Committee regulatory
"submission to the Australian Alfred Health Human Ethics Committee"
FAQ
What did Korro Bio (KRRO) announce regarding KRRO-121 on August 19, 2026?
Korro Bio announced it submitted materials to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 trial of KRRO-121. The study will assess safety, tolerability, pharmacokinetics, and effects in healthy volunteers and patients with Urea Cycle Disorders.
What is KRRO-121 in Korro Bio’s (KRRO) development pipeline?
KRRO-121 is described as a GalNAc-conjugated RNA editing oligonucleotide in development to potentially treat hyperammonemia in patients with Urea Cycle Disorders. The candidate targets elevated ammonia levels associated with these rare metabolic conditions as it advances toward first-in-human clinical evaluation.
What is the purpose of the planned Phase 1/2 trial for KRRO-121 by KRRO?
The planned Phase 1/2 trial is intended to determine safety and tolerability of escalating doses of KRRO-121, evaluate its pharmacokinetics, and assess its effects in both healthy volunteers and study participants diagnosed with Urea Cycle Disorders, including hyperammonemia manifestations.
Where will the KRRO-121 first-in-human study be overseen for Korro Bio (KRRO)?
Korro Bio states it has submitted to the Australian Alfred Health Human Ethics Committee to initiate the KRRO-121 Phase 1/2 trial. This committee review is a key ethical oversight step before enrolling healthy volunteers and Urea Cycle Disorder patients in the study.
How can investors find more information about the KRRO-121 clinical trial by KRRO?
Further information is available on ClinicalTrials.gov under identifier NCT 07773246. That listing is expected to include protocol details such as study design, eligibility criteria, endpoints, and locations for the first-in-human Phase 1/2 trial of KRRO-121 in Urea Cycle Disorders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
